Back to results
US 9,632,091 B2Granted
Compositions and methods for prostate cancer analysis
AssigneeGenentech, Inc.
InventorsSiminder Atwal, Jo-Anne Hongo, Mark Lackner, Elizabeth Punnoose, Bonnee Rubinfeld, Rajesh Vij
Life of this patent
Estimating the term…
Abstract
The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
Claims17
A method for diagnosing prostate cancer in a test subject, comprising:
- a) obtaining a blood sample comprising cancer cells of epithelial origin from the test subject;
- b) contacting the cancer cells of epithelial origin with an anti-STEAP1 antibody that specifically binds to the STEAP1 prostate-specific marker with a KD of ≦1000 nM;
- c) detecting whether STEAP1 is present on the cancer cells of epithelial origin by contacting the blood sample with an antibody that specifically binds to the STEAP1 prostate-specific marker antibody and detecting binding between STEAP1 and the antibody that specifically binds to the STEAP1 prostate-specific marker;
- and
- d) diagnosing the patient with prostate cancer when the presence of STEAP1 on the cancer cells of epithelial origin is detected;
- wherein the anti-STEAP-1 antibody is 15A5, produced by a hybridoma cell having a microorganism deposit number of PTA-12259, and
- wherein the detecting is by a method based on immunofluorescent microscopy, flow cytometry, fiber-optic scanning cytometry, or laser scanning cytometry.
4 more elements
A method of monitoring response to a prostate cancer therapy in a test subject, comprising:
- a) contacting a first group of cancer cells of epithelial origin with an anti-STEAP1 antibody that specifically binds to a prostate-specific marker with a KD of ≦1000 nM, wherein the first group of cancer cells are from a first blood sample taken from the test subject;
- b) determining the amount of the cancer cells in the first group that express the STEAP1 prostate-specific marker and/or the expression level of the STEAP1 prostate-specific marker in the cancer cells;
- c) contacting a second group of cancer cells of epithelial origin with the anti-STEAP1 antibody that specifically binds to a prostate-specific marker with a KD of ≦1000 nM, wherein the second group of cancer cells are from a second blood sample taken from the test subject after a test period of prostate cancer therapy;
- d) determining the amount of the cancer cells in the second group that express the STEAP1 prostate-specific marker and/or the expression level of the STEAP1 prostate-specific marker in the cancer cells;
- and
- e) comparing the amount of the cancer cells that express the STEAP1 prostate-specific marker and/or the STEAP1 prostate-specific marker expression level as determined in b) with that in d),
- wherein the anti-STEAP-1 antibody is 15A5, produced by a hybridoma cell having a microorganism deposit number of PTA-12259,
- wherein the determining is by a method based on immunofluorescent microscopy, flow cytometry, fiber-optic scanning cytometry, or laser scanning cytometry, and
- wherein a decrease in the amount of the cancer cells expressing the STEAP1 prostate-specific marker and/or a decrease in the STEAP1 prostate-specific marker expression level in the cancer cells indicates a response to the prostate cancer therapy in the test subject.
6 more elements
Dependencies are inferred from the claim text.